logo

Merck & Co Inc. (MRK)



Trade MRK now with
  Date
  Headline
10/15/2018 7:33:34 AM OncoSec Initiates KEYNOTE-890, Phase 2 Trial Of TAVO In Combination With Merck's KEYTRUDA For Late-Stage TNBC Treatment
10/9/2018 6:35:51 AM Merck’s Broad Oncology Pipeline To Be Highlighted At ESMO 2018 Congress
10/9/2018 2:13:56 AM Merck KGaA Announces First Presentation Of Phase III Data For Avelumab In Previously Untreated, Advanced Kidney Cancer
10/8/2018 6:04:38 AM Merck KGaA To Present Data On MS Portfolio At ECTRIMS 2018
10/4/2018 6:48:06 AM Merck Announces Week 96 Data From Pivotal Phase 3 DRIVE-AHEAD Study Of DELSTRIGO For HIV-1 In Treatment-Naïve Patients
10/4/2018 6:47:01 AM Merck’s HIV Therapy DELSTRIGO Meets Primary Efficacy Endpoint In Phase 3 DRIVE-SHIFT Study
9/27/2018 4:42:00 AM Immutep Enters Agreement With Merck/Pfizer To Investigate Combination Of APC Activator Efti With Avelumab
9/26/2018 6:46:20 AM Merck Rescinds Mandatory CEO Retirement Policy; CEO Kenneth Frazier To Remain In His Position Beyond December 2019
9/18/2018 2:43:57 AM Big Pharma Companies Dodging About $3.8 Bln In Tax Per Year: Oxfam
9/12/2018 6:51:15 AM Merck Says FDA Accepted For Review And Granted Priority Review To SBLA Seeking Approval For KEYTRUDA
9/11/2018 6:47:02 AM Merck Says ZERBAXA Met Primary Endpoints Of Non-Inferiority Compared To Meropenem In Pivotal Phase 3 Study
9/10/2018 6:46:59 AM Merck Says European Commission Approves KEYTRUDA In Combination With Pemetrexed And Platinum Chemotherapy